Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Conditional Marketing Authorisation for Venetoclax

It is intended for the treatment of adults with chronic lymphocytic leukaemia
17 Oct 2016
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 13 October 2016, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a conditional marketing authorisation for the medicinal product venetoclax (Venclyxto), intended for the treatment of chronic lymphocytic leukaemia (CLL). Venclyxto was designated as an orphan medicinal product on 6 December 2012.

The applicant for this medicinal product is AbbVie Ltd.

Venclyxto will be available as 10 mg, 50 mg and 100 mg film-coated tablets. The active substance of Venclyxto is venetoclax, an antineoplastic agent, which acts by inhibiting BCL-2 (B cell lymphoma-2), an anti-apoptotic protein overexpressed by B-cells in CLL, thus inducing tumour cell apoptosis.

The benefits shown in single arm studies with Venclyxto are its ability to produce responses in patients unsuitable for or refractory to B-cell receptor pathway inhibitors and other anticancer medicines.

The most common side effects are neutropenia, diarrhoea, nausea, anaemia, upper respiratory tract infection, fatigue, hyperphosphataemia, vomiting, and constipation. 

The full indication is:

“Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor. Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor."

It is proposed that Venclyxto be prescribed by physicians experienced in the treatment of CLL and the use of anticancer medicines.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 17 Oct 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.